Sweeny D J, Barnes S, Diasio R B
Division of Clinical Pharmacology, University of Alabama, Birmingham 35294.
Cancer Res. 1988 Apr 15;48(8):2010-4.
We have recently demonstrated that the major biliary metabolite of 5-fluorouracil (FUra) in cancer patients is a conjugate of the FUra catabolite 2-fluoro-beta-alanine (FBAL) and cholic acid (D.J. Sweeny, S. Barnes, G. Heggie, and R.B. Diasio. Proc. Natl. Acad. Sci. USA, 84:5439-5443, 1987). This finding prompted us to further examine the metabolism and biliary excretion of clinically relevant concentrations of the fluoropyrimidines FUra and 5-fluoro-2'-deoxyuridine (FdUrd) using the isolated perfused rat liver. During infusion of fluoropyrimidines, rates of appearance of metabolites in bile were similar with both 1 microM FUra and 1 microM FdUrd but were 9-fold higher with 25 microM FUra. Analysis by high performance liquid chromatography demonstrated that unmetabolized fluoropyrimidines and known catabolites (i.e., FBAL) accounted for less than 15% of the total metabolites in bile and that the majority of the biliary metabolites were eluted as three distinct nonpolar compounds. Fast atom bombardment-mass spectrometry demonstrated that these unique metabolites had molecular weights of 497 (peak 1), 497 (peak 2), and 481 (peak 3). These metabolites were hydrolyzed by cholylglycine hydrolase to FBAL and unconjugated bile acids that were identified by gas chromatography-mass spectrometry to be alpha-muricholic acid (peak 1), cholic acid (peak 2), and chenodeoxycholic acid (peak 3). Thus, the major biliary metabolites of FUra and FdUrd were identified as N-(bile acid)-FBAL conjugates. While the N-(bile acid)-FBAL conjugates were the major metabolites in bile, dihydroFUra was the major (greater than 70%) metabolite eliminated into perfusate. In summary, these results demonstrate that FUra and FdUrd undergo similar metabolism in the isolated perfused rat liver and, as was observed in humans, the major biliary fluoropyrimidine metabolites are conjugates of FBAL and bile acids.
我们最近证明,癌症患者体内5-氟尿嘧啶(FUra)的主要胆汁代谢物是FUra分解代谢物2-氟-β-丙氨酸(FBAL)与胆酸的结合物(D.J. Sweeny、S. Barnes、G. Heggie和R.B. Diasio。《美国国家科学院院刊》,84:5439 - 5443,1987年)。这一发现促使我们使用离体灌注大鼠肝脏进一步研究临床相关浓度的氟嘧啶FUra和5-氟-2'-脱氧尿苷(FdUrd)的代谢及胆汁排泄情况。在输注氟嘧啶期间,1 microM FUra和1 microM FdUrd时胆汁中代谢物的出现速率相似,但25 microM FUra时则高出9倍。高效液相色谱分析表明,未代谢的氟嘧啶和已知的分解代谢物(即FBAL)占胆汁中总代谢物的比例不到15%,且大部分胆汁代谢物以三种不同的非极性化合物形式洗脱出来。快原子轰击质谱显示,这些独特的代谢物分子量分别为497(峰1)、497(峰2)和481(峰3)。这些代谢物经胆酰甘氨酸水解酶水解为FBAL和未结合的胆汁酸,通过气相色谱 - 质谱鉴定为α-鼠胆酸(峰1)、胆酸(峰2)和鹅去氧胆酸(峰3)。因此,FUra和FdUrd的主要胆汁代谢物被鉴定为N -(胆汁酸)- FBAL结合物。虽然N -(胆汁酸)- FBAL结合物是胆汁中的主要代谢物,但二氢FUra是灌注液中消除的主要(超过70%)代谢物。总之,这些结果表明,FUra和FdUrd在离体灌注大鼠肝脏中经历相似的代谢,并且正如在人类中观察到的那样,主要的胆汁氟嘧啶代谢物是FBAL与胆汁酸的结合物。